Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) | PAR 21 122

Opportunity Information: Apply for PAR 21 122

The Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) funding opportunity (PAR 21-122) is a National Institutes of Health (NIH) discretionary grant program in the health area (CFDA 93.853) administered under the National Institute of Neurological Disorders and Stroke (NINDS) mission space. Its main purpose is to help researchers generate the key preclinical evidence needed to decide whether a proposed therapeutic agent is promising enough to move forward into more advanced, resource-intensive translational development programs. In practical terms, the FOA is aimed at bridging the gap between early discovery and later-stage NIH translational pipelines by supporting studies that show a drug candidate is behaving as expected in the body and producing meaningful effects in relevant disease models.

The scientific focus is on neurotherapeutic agents intended to treat neurological or neuromuscular disorders that align with NINDS priorities. The FOA supports multiple therapeutic modalities, including small molecules, biologics, and other biotechnology-derived products. Rather than funding clinical research, the announcement is explicitly limited to preclinical and translational-enabling work, and clinical trials are not allowed under this mechanism. The centerpiece of the work is to run pharmacokinetic (PK) studies to understand exposure, distribution, and how the agent moves through and is cleared from the body; pharmacodynamic (PD) studies to confirm that the agent engages the intended biological pathway or target and produces the expected mechanistic effects; and in vivo efficacy studies to test whether the agent produces beneficial outcomes in animal or other in vivo models that are appropriate for the disorder being targeted. Collectively, these data are meant to answer the basic translational question: does the agent show sufficient biological activity, in the right system, at feasible doses and exposure levels, to justify further development?

Structurally, the FOA uses an R61/R33 phased award approach. While the detailed milestone language is not provided in your excerpt, this type of mechanism generally supports an initial, time-limited phase focused on completing well-defined, go/no-go ready studies, followed by a second phase that is contingent on meeting prespecified milestones. In this context, that structure matches the program goal: rapidly produce decisive PK/PD and in vivo efficacy evidence, then continue only if the results support advancement. The FOA is also positioned as part of a broader IGNITE suite, with the explicit intent of advancing projects to the point where they can meet entry criteria for the Blueprint Neurotherapeutics Network or other translational development programs. That means the program is not just interested in basic proof-of-concept, but in generating the kind of disciplined, decision-quality dataset that downstream translational programs typically require.

From an eligibility standpoint, the applicant pool is broad and includes many public-sector, academic, nonprofit, and commercial entities. Eligible applicants include state, county, and local governments; special districts; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses. The FOA also highlights additional eligible applicant types that often appear as emphasized categories, such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and even non-domestic (non-U.S.) entities (foreign organizations). The inclusion of these categories signals that NINDS is open to a wide range of institutional settings, including organizations that may bring unique patient-community perspectives, disease-area expertise, or specialized technical capabilities relevant to translational neuroscience.

Key administrative details from the source information include the original opportunity closing date of 2024-10-21 and an award ceiling listed at $499,000. The listing also shows the opportunity was created on 2021-03-11. Although the excerpt does not specify the anticipated number of awards, budget period structure, or project duration, the ceiling indicates the program is designed to fund targeted, milestone-driven preclinical packages rather than large, open-ended development efforts.

Overall, this FOA is best understood as a translational acceleration opportunity for neurotherapeutic candidates that have moved beyond pure discovery but still need rigorous characterization and in vivo efficacy evidence before they are competitive for larger-scale development programs. It is intended to produce clear, actionable data about exposure, mechanism-linked activity, and efficacy in relevant in vivo models, helping investigators and NIH alike make an informed decision about whether the therapeutic agent should advance to the next stage of the neurotherapeutics pipeline.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853.
• This funding opportunity was created on 2021-03-11.
• Applicants must submit their applications by 2024-10-21. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $499,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 21 122

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: